Hangzhou Tigermed Consulting Yönetim

Yönetim kriter kontrolleri 4/4

Hangzhou Tigermed Consulting CEO'su Xiaochun Cao, Feb2017 tarihinde atandı, in görev süresi 7.75 yıldır. şirketin hisselerinin 6% doğrudan sahiptir ve bu hisselerin değeri CN¥ 2.94B dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 3.8 yıldır.

Anahtar bilgiler

Xiaochun Cao

İcra Kurulu Başkanı

CN¥1.2m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	7.8yrs
CEO sahipliği	6.0%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Xiaochun Cao'un ücretlendirmesi Hangzhou Tigermed Consulting'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	CN¥959m
Jun 30 2024	n/a	n/a	CN¥1b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥1m	n/a	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Jan 01 2023	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Jan 01 2022	n/a	n/a	CN¥3b
Sep 30 2021	n/a	n/a	CN¥2b
Jun 30 2021	n/a	n/a	CN¥2b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥836k	n/a	CN¥2b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥951m
Dec 31 2019	CN¥784k	n/a	CN¥842m

Tazminat ve Piyasa: Xiaochun 'nin toplam tazminatı ($USD 159.67K ), CN pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 265.87K ).

Tazminat ve Kazançlar: Xiaochun 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Xiaochun Cao (55 yo)

7.8yrs

Görev süresi

CN¥1,157,300

Tazminat

Dr. Xiaochun Cao, M.D., serves as Consultant at TigerYeah Capital. She co-founded Hangzhou Tigermed Consulting Co., Ltd. and served as its Chief Financial Officer since September 17, 2021 until October 21,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiaoping Ye	Co-Founder & Chairman	7.4yrs	CN¥2.92m	20.58% CN¥ 10.1b
Xiaochun Cao	Co-Founder	7.8yrs	CN¥1.16m	6% CN¥ 2.9b
Hao Wu	President & Executive Director	no data	CN¥2.61m	Veri yok
Chengcheng Yang	Chief Financial Officer	2.1yrs	CN¥1.42m	Veri yok
Zengyu Wen	Executive VP	no data	CN¥1.20m	Veri yok
Xiao Ri Li	Secretary	no data	CN¥656.80k	0.0017% CN¥ 837.5k
Tianrong Ji	Chief Investment Officer	no data	Veri yok	Veri yok
Guoyun Yu	Head of Accounting Department	no data	Veri yok	Veri yok
Jiansong Yang	Senior VP & Chief Scientific Officer	no data	Veri yok	Veri yok
Alan Liu	Chief Compliance Officer	no data	Veri yok	Veri yok
Xiao Li Shi	VP & Head of Data Resources Department	5.8yrs	Veri yok	Veri yok
Yun Jie Gong	Senior VP & Chief Quality Officer	no data	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 300347 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiaoping Ye	Co-Founder & Chairman	7.4yrs	CN¥2.92m	20.58% CN¥ 10.1b
Xiaochun Cao	Co-Founder	7.4yrs	CN¥1.16m	6% CN¥ 2.9b
Hao Wu	President & Executive Director	3.1yrs	CN¥2.61m	Veri yok
Zengyu Wen	Executive VP	1.5yrs	CN¥1.20m	Veri yok
Yuwen Liu	Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Binghui Zhang	Chairman of Supervisory Committee	4.6yrs	CN¥72.00k	Veri yok
Huagang Yuan	Independent Non Executive Director	1.5yrs	CN¥122.00k	Veri yok
Zhimin Chen	Shareholder Supervisor	4.6yrs	CN¥32.00k	Veri yok
Kai Yu Liu	Independent Non-Executive Director	4.6yrs	CN¥220.00k	Veri yok
Wenqing Lou	Employee Representative Supervisor	2.3yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300347 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Hangzhou Tigermed Consulting Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Hangzhou Tigermed Consulting Co., Ltd, Annual General Meeting, May 24, 2024

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Less than half of directors are independent

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Executive VP & Executive Director recently sold CN¥7.5m worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.56 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued

Hangzhou Tigermed Consulting Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.95 in 2Q 2023)

Dividend increased to CN¥0.57

Hangzhou Tigermed Consulting Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Hangzhou Tigermed Consulting Co., Ltd, Annual General Meeting, May 24, 2024

First quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.66 in 1Q 2023)

Hangzhou Tigermed Consulting Co., Ltd to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: CN¥2.34 (vs CN¥2.32 in FY 2022)

Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorates as stock falls 15%

Hangzhou Tigermed Consulting Co., Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.56 (vs CN¥0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.95 (vs CN¥0.78 in 2Q 2022)

New minor risk - Share price stability

Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023

Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023

Less than half of directors are independent

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Full year 2022 earnings released: EPS: CN¥2.32 (vs CN¥3.31 in FY 2021)

Executive VP & Executive Director recently sold CN¥7.5m worth of stock

Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) acquired Marti Farm d.o.o. za trgovinu i usluge.

Co-Founder recently sold CN¥477m worth of stock

Less than half of directors are independent

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: CN¥0.48 (vs CN¥0.61 in 3Q 2021)

Hangzhou Tigermed Consulting Co., Ltd. Announces Chief Financial Officer Changes

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd. to Report Q3, 2022 Results on Oct 25, 2022

Hangzhou Tigermed Consulting Co., Ltd. Announces Change of Employee Supervisor of Committee

Second quarter 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.92 in 2Q 2021)

Hangzhou Tigermed Consulting Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022

Hangzhou Tigermed Consulting Co., Ltd Approves Final Dividend to for the Year Ended December 31, 2021

First quarter 2022 earnings released: EPS: CN¥0.60 (vs CN¥0.52 in 1Q 2021)

Less than half of directors are independent

Hangzhou Tigermed Consulting Co., Ltd to Report Q1, 2022 Results on Apr 26, 2022

Hangzhou Tigermed Consulting Co., Ltd Declares Final Dividend for the Year Ended December 31, 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) announces an Equity Buyback for CNY 500 million worth of its shares.

Investor sentiment deteriorated over the past week

Hangzhou Tigermed Consulting Co., Ltd Provides Earnings Guidance for the Year of 2021

Third quarter 2021 earnings released: EPS CN¥0.61 (vs CN¥0.39 in 3Q 2020)

CFO, Deputy GM & Joint Company Secretary Gao Jun has left the company

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.92 (vs CN¥1.01 in 2Q 2020)

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) announces an Equity Buyback for CNY 500 million worth of its shares.

Joint Company Secretary Sau In Kwan has left the company

Investor sentiment deteriorated over the past week

Hangzhou Tigermed Consulting Co., Ltd Announces 2020 Final Distribution Plan to Be Implemented (A Shares), Payment Date on 01 June 2021

Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.52 (vs CN¥0.34 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥2.20 (vs CN¥1.13 in FY 2019)

New 90-day low: CN¥125

Hangzhou Tigermed Consulting Co.,Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥174

New 90-day high: CN¥154

New 90-day high: CN¥130